Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CRIPTO pseudogene 2 (CRIPTOP2) is a processed pseudogene in the human genome[4]. Pseudogenes are defective copies of protein-coding genes, often produced by retrotransposition, and typically lack the regulatory elements or sequence integrity necessary to produce a functional protein[2]. While some pseudogenes can regulate gene expression through complex RNA-mediated mechanisms (such as acting as miRNA decoys), most—including CRIPTOP2—are functionally inert and are not studied as therapeutic targets or biological receptors[2][4]. The parental gene, CRIPTO (TDGF1), is a growth factor involved in embryonic development and cancer, but CRIPTOP2 itself does not play an analogous role[4][2].\n\nIf you need information on the canonical, protein-coding CRIPTO (TDGF1, known as Teratocarcinoma-derived growth factor 1), please specify, as CRIPTOP2 and CRIPTO are distinct entities[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CRIPTO pseudogene 2 (CRIPTOP2).